Abdullah Büyükçelik

Prof. Abdullah Büyükçelik is a medical oncologist with a strong clinical and academic background. He earned his medical degree and completed his associate professorship at Ankara University Faculty of Medicine in 2006. Since 2009 he has been affiliated with Acibadem Health Group, where he combines patient care with ongoing clinical practice and collaboration. He is an active member of several professional organizations, including the Febrile Neutropenia Association, Medical Oncology Group, Internal Medicine Association, Medical Oncology Society, and Ankara Medical Oncology Association. His memberships reflect a commitment to multidisciplinary care, oncology research, and improving outcomes for patients with cancer and related complications.

Education

• 2006 Ankara University Faculty of Medicine / Associate Professor
• 2001 Ankara University Faculty of Medicine Medical Oncology
• 1996 Ankara University Faculty of Medicine Internal Medicine
• 1984 – 1990 Istanbul University Istanbul Faculty of Medicine

Experience

• 2009 Acibadem Health Group
• 2007 – 2009 Ankara University Faculty of Medicine Department of Medical Oncology / Bone Marrow Transplantation Unit
• 2001 – 2009 Department of Medical Oncology, Ankara University Faculty of Medicine
• 1999 – 2001 Ankara University Faculty of Medicine, Medical Oncology Residency
• 1996 – 1999 Ankara Sevgi Hospital / Internal Medicine Specialist

Memberships

• Febrile Neutropenia Association
• Medical Oncology Group
• Internal Medicine Association
• Medical Oncology Society
• Ankara Medical Oncology Association

Publications

• No abstract available. Angiotensin-converting enzyme inhibitors: do they contribute to delayed chemotherapy induced nausea and vomiting?
  Med Hypotheses, 73, 628-629, (2009) Dogan M, Yalcin B, Ozal FG, Buyukcelik A, Utkan G, Icli F, Dogan L.
• Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
  Med Oncol, 2009 Sep 29 Dincol D, Buyukcelik A, Dogan M, Akbulut H, Samur M, Demirkazik A, Senler FC, Onur H, Icli F.
• Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas.
  Yaman E, Yalcin B, Utkan G, Akbulut H, Isikdogan A, Sencan O, Buyukcelik A, Demirkazik A, Icli F. UHOD, 18, 79-84, (2008)
• The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
  Şencan O, Buyukcelik A, Yalcin B, Boruban M.C, Akbulut H, Demirkazik A, Senler F.C, Onur H, Icli F. Eur J Cancer Care, 17,26-32, (2008)
• Lung cancer metastasis mimicking gluteal abscess.
  South Med. J, 100, 334-335, (2007) Tek I, Iyidir OT, Utkan G, Ceyhan K, Buyukcelik A, Yalcin B, Demirkazik A.
• Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
  Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay F, Buyukcelik A. J. Surg. Oncol, 95, 507-512, (2007)
• Extranodal Hodgkin disease presenting with gluteal mass and hypercalcemia.
  South. Med. J. 99, 1149-1150, (2006) Utkan G, Buyukcelik A, Yalcin B, Tek I, Doruk H, Dincol D, Erekul S, Baykara M.
• Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  Buyukcelik A, Onur H, Akbulut H, Bulent Y, Ensari A, Utkan G, Onal BS, Icli F. Tumori, 91, 302-308, (2005)